appendix v - research samples
(3) cibmtr data. 2009.

(4) Wagner JE, Barker JN, Defor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. *Blood* 2002 September 1;100(5):1611-8.  
(5) Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. *N Engl J Med* **1998 November** 26;339(22):1565-77.  
(6) Rocha V, Cornish J, Sievers EL et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia.  
Blood **2001 May 15;97(10):2962-71.**
(7) Eapen M, Rubinstein P, Zhang MJ et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. *Lancet* 2007 June 9;369(9577):1947-54.  
(8) Cottler-Fox M, Cipolone K, Yu M, Berenson R, O'Shaughnessy J, Dunbar C.  
Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. *Exp Hematol* **1995**
April;23(4):320-2.  
(9) Dreger P, Viehmann K, Steinmann J et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. *Exp Hematol* 1995 February;23(2):147-54.  
(10) Lemoli RM, Tazzari PL, Fortuna A et al. Positive selection of hematopoietic CD34+
stem cells provides 'indirect purging' of CD34+ lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins. Bone Marrow Transplant **1994 April;13(4):465-71.**
(11) McNiece I, Briddell R, Stoney G et al. Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. J
Hematother 1997 February;6(1):5-11.  
(12) Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. *Blood* **1992** June 1;79(11):3036-44.  
(13) Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colonystimulating factor). *Blood* **1995 March 15;85(6):1666-72.**
(14) Korbling M, Huh YO, Durett A et al. Allogeneic blood stem cell transplantation:
peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. *Blood* **1995 October 1;86(7):2842-8.**
(15) Yeager A, Holand H, Mogul M. Transplantation of positively selected CD34+ cells from haploidentical parental donors for relapsed acute leukemia in children.  
Blood **1995;10, supplement:291a.**
(16) Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. *Blood* **1994 December** 1;84(11):3948-55.  
(17) Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. *J Clin Oncol* 2005 May 20;23(15):3447-54.  
(18) Handgretinger R, Klingebiel T, Lang P et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. *Bone Marrow Transplant* 2001 April;27(8):777-83.  
(19) Ortin M, Raj R, Kinning E, Williams M, Darbyshire P. Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarbine and anti-lymphocyte gamma-globulin. *Bone Marrow Transplant* 2002;30:359-66.  
(20) Focused Workshop on Haploidentical Stem Cell Transplantation, Naples, Italy.  
2004 Jul 8; 2004 p. 176-205.  
(21) Lang P, Klingebiel T, Bader P et al. Transplantation of highly purified peripheralblood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases. *Bone Marrow Transplant* **2004 January;33(1):25-32.**
(22) Sleight B, Cowan M, Horn B, Jaroscak J, McGuirk J, Gilman A. Selected haplocompatible donor stem cell transplntation in children. *Blood* 2006;108:5417a.  
(23) Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science* **2002 March**
15;295(5562):2097-100.  
(24) Leung W, Iyengar R, Turner V et al. Determinants of antileukemia effects of allogeneic NK cells. *J Immunol* 2004 January 1;172(1):644-50.  
(25) Lang P, Handgretinger R, Niethammer D et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. *Blood* **2003**
February 15;101(4):1630-6.  
(26) Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III
trial. *Lancet* **2005 August 27;366(9487):733-41.**
(27) van Burik JA, Carter SL, Freifeld AG et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow:
analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007 December;13(12):1487-98.  
(28) Eyrich M, Lang P, Lal S et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. *Br J Haematol* **2001 August;114(2):422-32.**
(29) Aversa F, Tabilio A, Velardi A. Transplantation of high risk acute leukemia with T
cell depleted stem cells from related donor with one fully mismatched HLA haplotype. *N Engl J Med* **1998;339:1186.**
(30) Lacerda JF, Martins C, Carmo JA et al. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen. *Biol* Blood Marrow Transplant **2003 October;9(10):633-42.**
(31) Benaim E, Hale G, Horwitz E, Leung W. Reduced Intensity Conditionin (RIC) in haploidentical Transplantation. *Blood* 2004;104:2147a.  
(32) Cooper N, Rao K, Gilmour K et al. Stem cell transplantation with reducedintensity conditioning for hemophagocytic lymphohistiocytosis. *Blood* **2006**
February 1;107(3):1233-6.  
(33) Rossi G, Giorgiani G, Comoli P et al. Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation. Bone Marrow Transplant **2003 March;31(6):437-40.**
(34) Chaudhury S, Auerbach AD, Kernan NA et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia 1. *Br J Haematol* 2008 March;140(6):644-55.  
(35) Hale G, Kasow K, Gan K, Horwitz E. Haploidentical stem cell transplantation with CD3 depleted mobilized peripheral blood stem cell grafts for children with hematologic malignancies. *Blood* 2009;106:2910a.  
(36) Kramer JH, Crittenden MR, DeSantes K, Cowan MJ. Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation. Bone Marrow Transplant 1997 March;19(6):607-13.  
(37) Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease 3. *Biol Blood Marrow Transplant* 2003 April;9(4):215-33.  
(38) Kaplan E, Meier P. Nonparametric estimation from incomplete observations.  
Journal of the American Statistical Association 1958;53:451-81.  
(39) Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. *Biometrics* **2005 June;61(2):540-5.**
(40) Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. *Blood* 2012 120: 3875-3881.  
(41) Jacobsohn DA. Acute graft-versus-host disease in children. Bone Marrow Transplant **2008 January;41(2):215-21.**
(42) Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.  
Transplantation 1974 October;18(4):295-304.  
(43) Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant **2003 April;9(4):215-33.**
(44) Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow* Transplant 2005 December;11(12):945-56.